"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...
Uncertainty around President Donald Trump’s tariff policies have sent the major averages on a roller-coaster ride and spurred ...
Pharma firms are among many pausing diversity programmes and promising domestic investment ...
CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Ireland is swimming in cash. US tech giants such as Apple, Microsoft, Google and Meta, and pharma groups including Pfizer and ...
The Irish economy is particularly vulnerable to US tariffs against the EU, as it exports relatively more to the US compared ...
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...
Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.
US President Donald Trump watched translated excerpts of an interview given by captivity survivor Eli Sharabi to the "Uvda" program, and invited him and other captivity survivors to the White ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback